

Rishi J Desai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7323991/publications.pdf>

Version: 2024-02-01

135
papers

4,725
citations

126907

33
h-index

118850

62
g-index

137
all docs

137
docs citations

137
times ranked

6801
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Medicare Claimsâ€‘Based Model to Predict Persistent Highâ€‘Dose Opioid Use After Total Knee Replacement. <i>Arthritis Care and Research</i> , 2022, 74, 1342-1348.	3.4	1
2	Calibrating Realâ€‘World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohnâ€™s Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 179-186.	4.7	5
3	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. <i>Journal of General Internal Medicine</i> , 2022, 37, 1917-1924.	2.6	5
4	Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2022, 79, 909-912.	1.9	2
5	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	1.9	5
6	Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. <i>Journal of Cardiac Failure</i> , 2022, 28, 1035-1039.	1.7	5
7	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 798-804.	0.9	76
8	Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. <i>Rheumatology</i> , 2022, 61, e236-e237.	1.9	3
9	Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. <i>JAMA Network Open</i> , 2022, 5, e226567.	5.9	16
10	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohnâ€™s disease. <i>Gut</i> , 2022, 71, 1781-1789.	12.1	11
11	Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. <i>Drug Safety</i> , 2022, 45, 493-510.	3.2	5
12	Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. <i>European Journal of Haematology</i> , 2021, 106, 273-280.	2.2	5
13	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
14	Prevalence, incidence and cause-specific mortality of rheumatoid arthritisâ€‘associated interstitial lung disease among older rheumatoid arthritis patients. <i>Rheumatology</i> , 2021, 60, 3689-3698.	1.9	43
15	Chronic prescription opioid use in pregnancy in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 504-513.	1.9	7
16	Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. <i>Rheumatology</i> , 2021, 61, 121-130.	1.9	41
17	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Journal of the American Heart Association</i> , 2021, 10, e020045.	3.7	9
18	Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100304.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Epidemiologic Characterization of Heart Failure with Reduced or Preserved Ejection Fraction Populations Identified Using Medicare Claims. <i>American Journal of Medicine</i> , 2021, 134, e241-e251.	1.5	14
20	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. <i>JAMA Network Open</i> , 2021, 4, e218816.	5.9	15
21	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009â€“2020. <i>Journal of the Endocrine Society</i> , 2021, 5, A250-A250.	0.2	1
22	External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure. <i>PLoS ONE</i> , 2021, 16, e0252903.	2.5	13
23	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021, 107, 1407-1416.	2.9	16
24	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Diseaseâ€“Modifying Antirheumatic Drugs. <i>ACR Open Rheumatology</i> , 2021, 3, 531-539.	2.1	7
25	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1427-1434.	1.9	6
26	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1242-1250.	3.4	9
27	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. <i>JAMA Network Open</i> , 2021, 4, e2135362.	5.9	1
28	Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013â€“2017. <i>American Journal of Nephrology</i> , 2021, 52, 919-928.	3.1	6
29	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. <i>Npj Digital Medicine</i> , 2021, 4, 170.	10.9	25
30	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1383-1391.	3.4	9
31	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 757-769.	1.9	8
32	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 401-408.	3.4	19
33	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020, 3, e1918962.	5.9	152
34	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. <i>Epidemiology</i> , 2020, 31, 82-89.	2.7	9
35	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1334-1342.	4.7	2
36	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 87.	7.4	9

#	ARTICLE	IF	CITATIONS
37	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. Crohn's & Colitis 360, 2020, 2, .	1.1	5
38	Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12095.	3.7	10
39	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Medicine, 2020, 17, e1003322.	8.4	27
40	Bias Implications of Outcome Misclassification in Observational Studies Evaluating Association Between Treatments and All-cause or Cardiovascular Mortality Using Administrative Claims. Journal of the American Heart Association, 2020, 9, e016906.	3.7	12
41	Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Annals of Hematology, 2020, 99, 2497-2505.	1.8	12
42	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	8.6	13
43	<p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p>. Clinical Epidemiology, 2020, Volume 12, 607-616.	3.0	15
44	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis and Rheumatology, 2020, 72, 1036-1038.	5.6	19
45	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatology, The, 2020, 2, e84-e98.	3.9	45
46	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study. ACR Open Rheumatology, 2020, 2, 222-231.	2.1	10
47	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clinical Pharmacology and Therapeutics, 2020, 108, 874-884.	4.7	2
48	Statin Lipophilicity and the Risk of Incident Heart Failure. Cardiology, 2020, 145, 375-383.	1.4	1
49	Medication Burden in Older Patients With Heart Failure: A Cohort Study of Medicare Beneficiaries. Journal of Cardiac Failure, 2020, 26, 742-744.	1.7	2
50	Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data. PLoS ONE, 2020, 15, e0241083.	2.5	7
51	Title is missing!. , 2020, 17, e1003322.		0
52	Title is missing!. , 2020, 17, e1003322.		0
53	Title is missing!. , 2020, 17, e1003322.		0
54	Title is missing!. , 2020, 17, e1003322.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 17, e1003322.		0
56	Title is missing!. , 2020, 17, e1003322.		0
57	Title is missing!. , 2020, 17, e1003322.		0
58	Title is missing!. , 2020, 17, e1003322.		0
59	Title is missing!. , 2020, 17, e1003322.		0
60	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration’s Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	3.2	5
61	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2019, 105, 1156-1163.	4.7	22
62	Using prescription claims to detect aberrant behaviors with opioids: comparison and validation of 5 algorithms. Pharmacoepidemiology and Drug Safety, 2019, 28, 62-69.	1.9	16
63	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. JAMA Network Open, 2019, 2, e198061.	5.9	48
64	Unraveling the Role of Nonsteroidal Antiinflammatory Drugs in the Link Between Osteoarthritis and Cardiovascular Disease via Causal Mediation Analysis: A Guide to Interpretation. Arthritis and Rheumatology, 2019, 71, 1776-1779.	5.6	4
65	Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. Arthritis and Rheumatology, 2019, 71, 712-721.	5.6	26
66	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	4.7	10
67	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases, 2019, 78, 456-464.	0.9	139
68	Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Internal Medicine, 2019, 179, 741.	5.1	27
69	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—a plasmode simulation study. Pharmacoepidemiology and Drug Safety, 2019, 28, 879-886.	1.9	4
70	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatology, 2019, 155, 700.	4.1	43
71	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Seminars in Arthritis and Rheumatism, 2019, 49, 222-228.	3.4	42
72	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	8.4	55

#	ARTICLE	IF	CITATIONS
73	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e027495.	1.9	25
74	Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. <i>BMJ: British Medical Journal</i> , 2019, 367, l5657.	2.3	304
75	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 113-121.	0.9	12
76	Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 892-900.	5.6	81
77	Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. <i>Blood</i> , 2019, 134, 2166-2166.	1.4	0
78	Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. <i>Journal of the American College of Cardiology</i> , 2018, 71, 994-1004.	2.8	69
79	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	55
80	Topiramate use early in pregnancy and the risk of oral clefts. <i>Neurology</i> , 2018, 90, e342-e351.	1.1	70
81	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. <i>BMJ: British Medical Journal</i> , 2018, 361, k1180.	2.3	27
82	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. <i>Arthritis Care and Research</i> , 2018, 70, 30-38.	3.4	10
83	Patterns of opioid initiation at first visits for pain in United States primary care settings. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 495-503.	1.9	30
84	Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. <i>Arthritis Care and Research</i> , 2018, 70, 791-796.	3.4	13
85	Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2429.	7.4	90
86	Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004700.	2.2	36
87	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1361-1370.	1.9	9
88	Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. <i>Journal of Rheumatology</i> , 2018, 45, 1240-1248.	2.0	45
89	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures. <i>JAMA Network Open</i> , 2018, 1, e180826.	5.9	64
90	Association between inflammation and systolic blood pressure in RA compared to patients without RA. <i>Arthritis Research and Therapy</i> , 2018, 20, 107.	3.5	18

#	ARTICLE	IF	CITATIONS
91	Anticonvulsants and the risk of perinatal bleeding complications. <i>Neurology</i> , 2018, 91, e533-e542.	1.1	4
92	Extension of Disease Risk Score—Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. <i>American Journal of Epidemiology</i> , 2018, 187, 2439-2448.	3.4	8
93	Network-based approach to prediction and population-based validation of in silico drug repurposing. <i>Nature Communications</i> , 2018, 9, 2691.	12.8	351
94	Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. <i>American Journal of Psychiatry</i> , 2018, 175, 564-574.	7.2	61
95	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Circulation</i> , 2018, 138, 1116-1126.	1.6	108
96	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. <i>American Journal of Kidney Diseases</i> , 2018, 72, 178-187.	1.9	15
97	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. <i>PLoS ONE</i> , 2018, 13, e0193622.	2.5	33
98	A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent. <i>Epidemiology</i> , 2017, 28, 249-257.	2.7	164
99	Pregabalin use early in pregnancy and the risk of major congenital malformations. <i>Neurology</i> , 2017, 88, 2020-2025.	1.1	56
100	Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States. <i>Psychiatric Services</i> , 2017, 68, 1112-1119.	2.0	41
101	Lithium Use in Pregnancy and the Risk of Cardiac Malformations. <i>New England Journal of Medicine</i> , 2017, 376, 2245-2254.	27.0	183
102	The Potential Return on Public Investment in Detecting Adverse Drug Effects. <i>Medical Care</i> , 2017, 55, 545-551.	2.4	6
103	Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. <i>Obstetrics and Gynecology</i> , 2017, 129, 174-184.	2.4	77
104	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 613-625.	1.4	2
105	Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2017, 37, 1322-1327.	2.6	16
106	Use of large healthcare databases for rheumatology clinical research. <i>Current Opinion in Rheumatology</i> , 2017, 29, 138-143.	4.3	4
107	Placental Complications Associated With Psychostimulant Use in Pregnancy. <i>Obstetrics and Gynecology</i> , 2017, 130, 1192-1201.	2.4	50
108	Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor- α inhibitors or nonbiologic agents: a cohort study. <i>Cmaj</i> , 2017, 189, E1438-E1447.	2.0	14

#	ARTICLE	IF	CITATIONS
109	Alendronate and Hip Fracture in Patients Using Glucocorticoids. JAMA - Journal of the American Medical Association, 2017, 318, 1711.	7.4	0
110	The “Dry-Run” Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	3.4	15
111	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ: British Medical Journal, 2017, 356, j895.	2.3	50
112	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 159.	3.5	37
113	Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 809-814.	0.9	30
114	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis and Rheumatology, 2016, 68, 1183-1189.	5.6	27
115	Tumor Necrosis Factor- α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology, 2016, 27, 414-422.	2.7	18
116	Identification of smoking using Medicare data - a validation study of claims-based algorithms. Pharmacoepidemiology and Drug Safety, 2016, 25, 472-475.	1.9	55
117	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry, 2016, 73, 938.	11.0	206
118	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care and Research, 2016, 68, 1078-1088.	3.4	24
119	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. American Journal of Epidemiology, 2016, 183, 949-957.	3.4	24
120	Suppression of Substance Abuse Claims in Medicaid Data and Rates of Diagnoses for Non-Substance Abuse Conditions. JAMA - Journal of the American Medical Association, 2016, 315, 1164.	7.4	12
121	Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstetrics and Gynecology, 2015, 126, 271-278.	2.4	15
122	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	7.4	198
123	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Research and Therapy, 2015, 17, 83.	3.5	13
124	Disease-Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study. Arthritis Care and Research, 2015, 67, 457-466.	3.4	28
125	Predictors of Treatment Initiation with Tumor Necrosis Factor- α Inhibitors in Patients with Rheumatoid Arthritis. Journal of Managed Care Pharmacy, 2014, 20, 1110-1120.	2.2	29
126	Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women. Obstetrics and Gynecology, 2014, 123, 997-1002.	2.4	291

#	ARTICLE	IF	CITATIONS
127	Tumor Necrosis Factor- α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study. Journal of Rheumatology, 2014, 41, 2129-2136.	2.0	28
128	Reply. Obstetrics and Gynecology, 2014, 124, 638.	2.4	0
129	Exploratory Evaluation of Medication Classes Most Commonly Involved in Nursing Home Errors. Journal of the American Medical Directors Association, 2013, 14, 403-408.	2.5	25
130	Analgesic Medication Errors in North Carolina Nursing Homes. Journal of Pain and Palliative Care Pharmacotherapy, 2013, 27, 125-131.	0.8	10
131	Anticoagulant medication errors in nursing homes: Characteristics, causes, outcomes, and association with patient harm. Journal of Healthcare Risk Management: the Journal of the American Society for Healthcare Risk Management, 2013, 33, 33-43.	0.7	9
132	Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2012, 46, 1491-1505.	1.9	15
133	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	1.9	15
134	Medication Errors During Patient Transitions into Nursing Homes: Characteristics and Association With Patient Harm. American Journal of Geriatric Pharmacotherapy, 2011, 9, 413-422.	3.0	32
135	Drug use trends for arthritis and other rheumatic conditions and effect of patient's age on treatment choice. North Carolina Medical Journal, 2011, 72, 432-8.	0.2	3